Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Per Larsson

Showing results (151-160 of 158) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 158 results.
Bioinformatics (Oxford, England)|February 15, 2013
GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkitSander Pronk, Szilárd Páll, Roland Schulz, et al.
Communications Biology|October 2, 2018
Flagella-mediated secretion of a novel <i>Vibrio cholerae</i> cytotoxin affecting both vertebrate and invertebrate hostsMitesh Dongre, Bhupender Singh, Kyaw Min Aung, et al.
Cancers|September 25, 2020
Establishment of Prostate Tumor Growth and Metastasis Is Supported by Bone Marrow Cells and Is Mediated by PIP5K1α Lipid KinaseRichard Karlsson, Per Larsson, Regina Miftakhova, et al.
Arthritis and Rheumatism|September 6, 2005
Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept studyBo Baslund, Niels Tvede, Bente Danneskiold-Samsoe, et al.
Science (New York, N.Y.)|April 21, 2012
Recent plant diversity changes on Europe's mountain summitsHarald Pauli, Michael Gottfried, Stefan Dullinger, et al.
BMJ (Clinical Research Ed.)|December 3, 2020
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trialMerete Lund Hetland, Espen A Haavardsholm, Anna Rudin, et al.
The Lancet. Rheumatology|March 25, 2026
Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trialJon Lampa, Dan Nordström, Ronald van Vollenhoven, et al.
Annals of the Rheumatic Diseases|July 9, 2023
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trialMikkel Østergaard, Ronald F van Vollenhoven, Anna Rudin, et al.
Pageof 16

Showing results (151-160 of 158) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 158 results.
Bioinformatics (Oxford, England)|February 15, 2013
GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkitSander Pronk, Szilárd Páll, Roland Schulz, et al.
Communications Biology|October 2, 2018
Flagella-mediated secretion of a novel <i>Vibrio cholerae</i> cytotoxin affecting both vertebrate and invertebrate hostsMitesh Dongre, Bhupender Singh, Kyaw Min Aung, et al.
Cancers|September 25, 2020
Establishment of Prostate Tumor Growth and Metastasis Is Supported by Bone Marrow Cells and Is Mediated by PIP5K1α Lipid KinaseRichard Karlsson, Per Larsson, Regina Miftakhova, et al.
Arthritis and Rheumatism|September 6, 2005
Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept studyBo Baslund, Niels Tvede, Bente Danneskiold-Samsoe, et al.
Science (New York, N.Y.)|April 21, 2012
Recent plant diversity changes on Europe's mountain summitsHarald Pauli, Michael Gottfried, Stefan Dullinger, et al.
BMJ (Clinical Research Ed.)|December 3, 2020
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trialMerete Lund Hetland, Espen A Haavardsholm, Anna Rudin, et al.
The Lancet. Rheumatology|March 25, 2026
Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trialJon Lampa, Dan Nordström, Ronald van Vollenhoven, et al.
Annals of the Rheumatic Diseases|July 9, 2023
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trialMikkel Østergaard, Ronald F van Vollenhoven, Anna Rudin, et al.
Pageof 16